Kopran’s wholly owned subsidiary company -- Kopran Research Laboratories has received approval from Unites States Food and Drug Administration (USFDA) for supply of API Atenolol to the US market. The company had filed the DMF of Atenolol, which has now been approved by the USFDA
Earlier the subsidiary’s active Pharmaceutical Ingredients Manufacturing facility at Mahad was inspected by the USFDA in January 2019 without any observation under Para 483.
Kopran is working towards creating and maintaining a global presence. Presence in Africa through Kampala Pharmaceutical Industries (KPI), a pharmaceutical company engaged in the manufacture and marketing of finished dosage forms in Uganda.
